Control Battle Erupts at Israeli Healthcare Firm Novolog Amid Share Decline and Investment Offer
How 2 Israeli newsrooms covered this story — translated into English and compared side by side.
By גלי וינרב
What happened
A control dispute has emerged at Israeli healthcare firm Novolog between major shareholder Ehud Pozis and investor Eli Dahan, who offered a 100 million shekel investment for a 21% stake. Novolog’s shares have dropped sharply, and tensions rose after Pozis’s son Oded joined the board. Pozis seeks to replace the board to block the deal, while Dahan aims to gain effective control. The company faces financial losses and operational issues following a failed ERP system upgrade.
- 01Novolog faces a control battle between major shareholder Ehud Pozis and investor Eli Dahan.
- 02Dahan offers 100 million shekels for 21% of Novolog, whose shares fell 77% since 2022.
- 03Ehud Pozis plans to replace the board to block Dahan’s investment proposal.
- 04Novolog’s shares dropped from a 1.8 billion shekel peak to 415 million shekels.
- 05The company suffered a 39 million shekel loss in 2023 due to write-downs and ERP failures.
- 06Novolog has 163 million shekels cash but faces operational and financial challenges.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Ask About This Story
Duki reads it, and every newsroom on the same story, then answers with sources.
Full coverage · 2 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
